Inpharmatica Announces ISO 9001 Certification for its ADME Business
News May 15, 2006
Inpharmatica Ltd. has announced the award of ISO 9001:2000 quality certification for its comprehensive ADME business, Admensa™.
The internationally accepted ISO 9001 Certification recognises Inpharmatica's commitment to a quality of service and customer care within its Admensa division.
The high level of customer care and service is bringing Inpharmatica an expanding list of international companies who have chosen to work with Inpharmatica to address their ADME needs.
40 customers have signed up to use Admensa, including recent additions Ark Therapeutics Group PLC, KuDOS Pharmaceuticals Limited, iQur Limited and Canbex Therapeutics Limited, a spin out from UCL's Wolfson Institute.
Admensa is designed to offer a combination of ADME optimisation expertise, proprietary in silico tools, laboratory services and consulting, to enable early selection of compounds with an optimal balance of drug like properties.
A module of Admensa, Admensa Interactive™, Inpharmatica's in silico optimisation platform for drug discovery scientists, has recently been enhanced to offer improved QSAR ADME models, P450 metabolism models and unique compound prioritisation and selection methods within an intuitive, interactive design environment.
Admensa itself is an integral component of Inpharmatica's gene-to-candidate technology platform which integrates biology- and chemistry-based drug discovery activities.
The complete platform is designed to optimise target selection based on druggability, and enables identification of hits and selection of high quality leads and pre-clinical candidates, which are prioritised on the basis of good drug-like characteristics and clinical indication.
Commenting on the announcement, John Lisle, Inpharmatica's CEO, said, "This ISO 9001 certification means that Inpharmatica's customers can be even more confident that they will receive an excellent product and an excellent level of service and customer care."
"We have already seen high levels of customer satisfaction and the company is enjoying the extra sales that this brings."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018